ClinicalTrials.gg

Program

donanemab

Also written as “Donanemab”, “LY3002813” and “LY3002813-IV”.

Its studies are mostly in Alzheimer Disease · Cognitive Dysfunction, led by Eli Lilly.

Furthest: phase 4, since Sep 18, 202614 company-led studies, 7 open or runningNext primary completion: Nov 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly147 open or runningphase 4since Sep 18, 2026Apr 18, 2013Nov 2027phase 3 · NCT05026866

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 18, 2013First study: phase 1 study in Alzheimer DiseaseFirst studyNCT01837641 · 63 enrolled · United States, Japan
  2. Dec 4, 2015Phase 1 study in Alzheimer DiseaseNCT02624778 · 61 enrolled · United States, Japan
  3. Dec 5, 2017Phase 2 study in Alzheimer DiseaseNCT03367403 · 272 enrolled · United States, Canada
  4. Jun 17, 2020Phase 3 study in Alzheimer DiseaseNCT04437511 · 1,736 enrolled · United States, Australia, Canada and more
  5. Nov 9, 2020Phase 2 study in Alzheimer DiseaseNCT04640077 · 95 enrolled · United States, Canada
  6. Aug 27, 2021Phase 3 study in Alzheimer DiseaseNCT05026866 · 2,996 enrolled · United States, Japan, Puerto Rico
  7. Oct 26, 2021Phase 3 study in Cognitive DysfunctionNCT05108922 · 148 enrolled · United States
  8. Aug 18, 2022Phase 3 study in Alzheimer DiseaseNCT05508789 · 1,500 enrolled · Argentina, Australia, China and more
  9. Sep 6, 2022Phase 1 study in HealthyNCT05533411 · 36 enrolled · China
  10. Oct 3, 2022Phase 1 study in HealthyNCT05567159 · 42 enrolled · United States
  11. Apr 30, 2026Phase 3 study in Alzheimer DiseaseNCT07571161 · 140 planned · China
  12. May 11, 2026Phase 2 study in Cognitive DysfunctionNCT07589595 · 350 planned · United States, Japan, South Korea and more
  13. May 15, 2026Phase 3 study in Alzheimer DiseaseNCT07602582 · 550 planned · United States, Japan, Puerto Rico
  14. Sep 18, 2026Phase 4 study in Alzheimer DiseaseNCT07838155 · 50 planned · India

Ahead

  1. Nov 2027Primary completion: phase 3 study in Alzheimer DiseaseNCT05026866
  2. May 2028Primary completion: phase 3 study in Alzheimer DiseaseNCT05508789
  3. Aug 2028Primary completion: phase 2 study in Cognitive DysfunctionNCT07589595
  4. Sep 2029Primary completion: phase 3 study in Alzheimer DiseaseNCT07602582

TargetBeta

APP →read by rule
“Amyloid-beta A4 protein disrupting agent”ChEMBL 37, by rule

Other programs on APP

ProgramCompanyFurthest phaseStudies
ABBV-1758AbbViephase 21
ALIA-1758AbbViephase 11

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07838155Alzheimer Disease · India4Not yet recruitingSep 203050
NCT07602582Alzheimer Disease · United States, Japan, Puerto Rico3RecruitingSep 2029550
NCT07589595Cognitive Dysfunction · United States, Japan, South Korea and more2RecruitingAug 2028350
NCT07571161Alzheimer Disease · China3RecruitingApr 2030140
NCT05567159Healthy · United States1CompletedJul 14, 202342
NCT05533411Healthy · China1CompletedJan 5, 202336
NCT05508789Alzheimer Disease · Argentina, Australia, China and more3Active, not recruitingMay 20281,500
NCT05108922Cognitive Dysfunction · United States3CompletedSep 9, 2022148
NCT05026866Alzheimer Disease · United States, Japan, Puerto Rico3Active, not recruitingNov 20272,996
NCT04640077Alzheimer Disease · United States, Canada2CompletedFeb 27, 202495
NCT04437511Alzheimer Disease · United States, Australia, Canada and more3Active, not recruitingApr 14, 20231,736
NCT03367403Alzheimer Disease · United States, Canada2CompletedDec 4, 2020272
NCT02624778Alzheimer Disease · United States, Japan1CompletedAug 28, 201961
NCT01837641Alzheimer Disease · United States, Japan1CompletedAug 24, 201663

How it is read

Names in the registry

  • “Donanemab”, 11 entries
  • “donanemab”, 1 entry
  • “LY3002813”, 1 entry
  • “LY3002813-IV”, 1 entry
  • “LY3002813-SC”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.